HCPLive Network

STAMPEDE Trial: Bariatric Surgery Beats Medical Management for Obese Patients with Diabetes

For obese individuals with type 2 diabetes mellitus (DM), better glycemic control often occurs when body mass index (BMI) drops. Achieving long-term weight loss, however, is very difficult. Despite the growing popularity of the procedure in this patient population, the literature lacks rigorous examination of the effectiveness of bariatric surgery compared to intensive medical therapy for optimizing glycemic control in patients with type 2 diabetes.
At the American College of Cardiology 2014 Scientific Session, held in Washington, DC, the Cleveland Clinic’s Sangeeta Kashyap, MD, principal investigator for the STAMPEDE trial, presented good results for surgical patients at the one-year mark.
In a study of 150 moderately to severely obese patients with type 2 diabetes (BMI 27-43 kg/m2 and HbA1c >7.0%), subjects were randomized 1:1:1 to receive intensive medical therapy alone, medical therapy plus gastric bypass (the Roux-en-Y procedure), or medical therapy plus sleeve gastrectomy. At the 12-month mark, STAMPEDE researchers reported 93% retention, with the population for primary analysis being 41, 50, and 49 subjects for the three arms respectively.
The study population was relatively young (mean age slightly less than age 50), had poor glycemic control (mean HbA1c 8.9, 9.3, and 9.5 among the three groups), and consisted of slightly more than 50% females. Mean body mass index for study subjects was 37. Most patients were on more than three diabetes medications, and nearly half were receiving insulin.
The primary endpoint was defined as the success rate of achieving HbA1c less than or equal to 6%. Secondary endpoints, in addition to safety and adverse events, included change in medications, fasting plasma glucose (FPG), BMI, lipids, blood pressure, or highly-sensitive C-reactive protein. Intensive medical care, delivered to all treatment arms, followed the ADA clinical care guidelines. In addition to optimal medical management, this included diet and lifestyle counseling, frequent home glucose monitoring, and regularly scheduled visits with physicians and allied health professionals.
In comparing both gastric bypass and sleeve gastrectomy against medical therapy, both surgical procedures outperformed medical therapy alone in all primary and secondary outcomes. All measures reached statistical significance. Notably, 42% of the bypass patients and 27% of the sleeve patients achieved HbA1c of less than or equal to 6% with no diabetes medications. The large majority (92 to 96%) of the surgical treatment arms no longer required insulin at 12 months post surgery, while just over 40% of the medical management patients were still using insulin. A total of 44 study participants in the surgical arms were taking no cardiovascular medications at one year after study enrollment, as compared with zero medical therapy patients at 12 months (P< .001 for both arms). At the beginning of the study period, just five of the surgical patients had been able to avoid cardiovascular medications.
As expected, BMI dropped nine to ten points in surgery recipients, but losses of almost two points were also seen in the medical therapy arm. Quality of life indices were also higher in surgical patients.
Study subjects, especially bypass recipients, experienced more adverse events then those undergoing medical therapy, but the study authors report that the complication rate was similar to other observational studies with gastric bypass, and no long-term morbidity was reported. Four of the Roux-en-Y patients required reoperation for anastomotic ulcer.
Study limitations include small sample size and single site design, as well as short follow-up period. The authors note that subjects will be followed out to four years, and recommended larger multisite studies to validate findings.
In a press conference following the morning’s Late-Breaking Clinical Trials session, Amit Khera, MD, University of Texas Southwestern Medical Center, remarked that long-term follow-up of these patients will show whether improved glycemic control from gastric bypass surgery will have a durable effect. He said follow-up care will also help clarify the outcome for patients with type 2 diabetes and only moderate obesity who receive gastric bypass.
He also noted the importance of gathering quality of life data for these patients, and remarked on the significant increases seen in quality of life for surgery patients, even taking into consideration the burden of surgery recovery.

Further Reading
The FDA has approved Baxter’s Rixubis [Coagulation Factor IX (Recombinant)], an intravenous prophylactic treatment intended to control and prevent bleeding episodes and assist with perioperative management for children 12 years and younger with hemophilia B.
A compound known as P7C3-S243 appears to keep axons from degenerating after a blast injury, a University of Iowa mouse study has found. “We propose that P7C3-S243 serves as a chemical scaffold upon which new drugs can be designed to treat patients with condition of axonal degradation such as occurs in traumatic brain injury or other neurodegenerative disease,” the researchers wrote
Nancy Chiaravalloti, PhD, shares how cognitive function impacts patients with progressive multiple sclerosis at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
A new set of guidelines from the American College of Physicians (ACP) advises physicians to prescribe exercises and behavioral therapy—not drugs—as first-line treatment for many patients with urinary incontinence (UI).
Using an experimental and highly sensitive test for cardiac troponin, a team of Johns Hopkins researchers found undetected signs of heart muscle damage in people with diabetes and pre-diabetes. That may suggest that hypoglycemia directly damages the heart.
As reported in the EMBO Molecular Medicine journal, researchers have discovered there are several types of dendritic cells within human skin that play a role in both the earlier and more advances stages of psoriasis.
From 2007 to 2011, there were nearly 10,000 emergency hospitalizations per year for unsupervised prescription medication ingestion by young children, according to a study published online Sept. 15 in Pediatrics.
More Reading
The FDA has approved Baxter’s Rixubis [Coagulation Factor IX (Recombinant)], an intravenous prophylactic treatment intended to control and prevent bleeding episodes and assist with perioperative management for children 12 years and younger with hemophilia B.